NDAORALSOLUTIONPriority Review
Approved
May 2013
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
2
Data completeness
6/8 — Strong
Priority Review
NYMALIZE (nimodipine) by R-Pharm US is calcium channel antagonists [moa]. Approved for subarachnoid hemorrhage. First approved in 2013.
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
NYMALIZE (nimodipine) is an oral dihydropyridine calcium channel blocker indicated for subarachnoid hemorrhage, dementia, and HIV infections. It works by antagonizing L-type calcium channels to reduce vasospasm and improve cerebral blood flow. The oral solution formulation (approved 2013) represents a reformulation of the intravenous standard of care.
$0.066BPart D
Peak11.9 years to LOEPeak lifecycle stage with modest Part D spending ($66K in 2023) indicates a niche product with limited commercial scale; the small R-Pharm US team likely focuses on targeted account management rather than broad market expansion.
Mechanism of Action
Calcium Channel Antagonists
Pharmacologic Class:
Dihydropyridine Calcium Channel Blocker
Indications (1)
Clinical Trials (2)
Acupuncture Combined With Nimodipine for Prevention of Post-stroke Dementia
Started Feb 2021
Randomized, Double-Blind, Placebo-Controlled Trial of Nimodipine for the Neurological Manifestations of HIV-1
36 enrolled
AIDS Dementia ComplexHIV Infections
Career Relevance
Worked on NYMALIZE at R-Pharm US? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.